Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has provided an update.
JCR Pharmaceuticals Co., Ltd. has announced its relationship with MEDIPAL HOLDINGS CORPORATION, which is its largest shareholder with a 23.86% voting rights ownership. The companies have a business alliance to enhance corporate value and growth, leveraging MEDIPAL’s distribution strengths and JCR’s pharmaceutical R&D capabilities. Recent agreements between the two include exclusive negotiation rights for the global commercialization of JCR’s new drug candidates targeting ultra-rare lysosomal storage diseases, and licensing agreements for treatments like JR-471 and JR-446. These collaborations are expected to bolster JCR’s industry positioning and operational capabilities.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on developing treatments for rare diseases and complex healthcare challenges. With a 50-year legacy in Japan, the company is expanding its global presence in the U.S., Europe, and Latin America. JCR is known for its scientific expertise and unique technologies that aid in the research, development, and delivery of next-generation therapies. Their approved products in Japan include treatments for growth disorders, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia, while investigational products target rare diseases such as MPS I, MPS II, and MPS IIIA and B.
Average Trading Volume: 1,129,338
Technical Sentiment Signal: Sell
Current Market Cap: Yen64.72B
For an in-depth examination of 4552 stock, go to TipRanks’ Overview page.